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the opportunity to evaluate several diagnostic workflow from a combined clinical 
and economic perspective using a cost-effectiveness analysis.
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Objectives: Although apheresis is an important treatment for reducing LDL-C in 
familial hypercholesterolemia (FH) patients, little is known about its treatment pat-
terns. We conducted a systematic review to assess the efficacy/effectiveness, prac-
tice patterns, cost, and clinical guidelines for apheresis in FH patients. MethOds: 
Electronic databases were searched for publications of apheresis in FH patients. 
Inclusion criteria include: articles in English published 2000-2013, description of 
practice patterns, efficacy/effectiveness, and costs. Data were stratified by country 
and FH genotype where possible. Results: Thirty-seven studies met the inclusion 
criteria: 8 open-label clinical trials, 11 observational studies, 16 reviews/guidelines, 
and 2 health technology assessments. Of the 19 clinical and observational studies, 
6 assessed only homozygous FH (HoFH) patients, 4 assessed only heterozygous FH 
(HeFH) patients, 6 included HoFH and HeFH patients, and 3 did not specify type of 
FH. The prevalence of FH is not well characterized by country and underdiagnosis 
is a barrier to optimal FH treatment. Apheresis guidelines recommend weekly/bi-
weekly treatments conducted at apheresis centers that may last ≥ 3 hours per ses-
sion. Apheresis may be recommended as first-line treatment in HoFH patients and 
after drug therapy failure in HeFH patients. Studies reported a range of LDL-C reduc-
tion after apheresis: HoFH: 57-75%; HeFH: 58-63%. Eight studies reported apheresis 
costs. Cost (USD 2013) per apheresis session ranged from $2,200-$4,300 in the US, 
$2,150-$2,600 in the UK, $1700-$1850 in Germany and France, and $2,350-$2,750 
in Australia. Calculated annual costs may reach $88,400-$225,000 per patient for 
weekly treatment. cOnclusiOns: LDL-C apheresis treatment is necessary for FH 
patients when drug therapy is inadequate. While apheresis reduces LDL-C, high 
per-session costs and the frequency of guideline-recommended treatment result 
in substantial annual costs. The costs and the inconvenience of apheresis sessions 
are barriers in optimal treatment of FH.
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Objectives: Our objective was to estimate the impact of catheter-based renal 
denervation plus standard of care (RDN) versus standard of care alone (SoC) on 
European stage-1 hypertension patients with different cardiovascular risk factor 
profiles. MethOds: We simulated resistant hypertension cohorts with different 
cardiovascular risk factor profiles (CVRPs) who had stage-1 hypertension despite 
adequate treatment with SoC. Six different cohorts with permutations of starting 
ages of 40, 55, or 70 years; and low and high CVRPs based on JNC7 guidelines were 
modeled. Interventions were RDN plus SoC with three or more anti-hypertensives 
including a diuretic at full doses or SoC alone. As observed in a recent prospective 
uncontrolled pilot study, the impact of a 13 mmHg reduction in systolic blood pres-
sure (SBP) – from a baseline SBP of 151 mmHg – was evaluated. Undiscounted life 
year (LY) and quality-adjusted life year (QALY) gain was computed using a published 
life-time Markov simulation model based on multivariate risk equations. Results: 
Across the studied age groups and cardiovascular risk profiles, catheter-based renal 
denervation was associated with gains in unadjusted (0.51-1.48 LYs) and quality-
adjusted life expectancy (0.39-1.20 QALYs). Younger age and higher cardiovascular 
risk profile led to numerically higher increments. The cohort-specific LY and QALY 
gains were projected as follows: 1) 40 year old cohorts: low CV risk profile: 0.84 LYs/ 
0.78 QALYs; high CV risk profile: 1.48 LYs/ 1.20 QALYs; 2) 55 year old cohorts: low CV 
risk profile: 0.69 LYs/ 0.60 QALYs; high CV risk profile: 1.29 LYs/ 0.95 QALYs; 3) 70 year 
old cohorts: low CV risk profile: 0.51 LYs/ 0.39 QALYs; high CV risk profile: 0.99 LYs/ 
0.68 QALYs. cOnclusiOns: RDN, when used to treat moderate treatment-resistant 
hypertension, is associated with clinically significant increases in life expectancy. 
These model-based findings need to be confirmed in clinical trials.
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Objectives: The objective of this review was to investigate the use of MIS and intra-
operative imaging technologies in the treatment and management of persons with 
ICH. MethOds: A systematic search of the published literature was undertaken in 
February 2014, using the Embase, PubMed and CRD York bibliographic databases. Key 
society websites were also searched for relevant ICH practice guidelines. Studies and 
guidelines reporting on MIS techniques in persons eligible for treatment for Primary 
ICH were included. Results: 1042 citations were retrieved, of which 190 full-text 
articles were reviewed. Six practice guidelines, 4 Systematic reviews, 10 RCTs and 3 
Economic evaluations were included. All 4 systematic reviews of RCT data showed 
consistent results in favour of MIS versus medical management (MM) or craniotomy 
(CR) for both efficacy (mortality and/ or mortality and dependent living benefit) and 
safety (lower rebleeding and higher hematoma volume reduction) vs. CR. A statisti-
cally significant reduction in the relative risk (RR) of death ranging from 34-71% for 
patients treated with MIS as opposed to CR or MM was reported in all 4 reviews. Three 
ICH guidelines (Europe, Japan and USA) recommended the use MIS in specific circum-
of atherothrombotic events (when combined with antiplatelet therapy) following an 
acute coronary syndrome. Use, safety and effectiveness of rivaroxaban in real-life 
settings need to be monitored to understand its value and comply with regulatory 
requirements. Objectives: To develop a pharmacoepidemiologic PASS programme 
to characterize post-authorization rivaroxaban use and relevant outcomes related to 
safety (intracranial, gastrointestinal, and urogenital haemorrhage) and effectiveness 
(myocardial infarction, ischaemic stroke and thromboembolic events). MethOds: 
European sources of longitudinal observational health care data were identified 
that contained population-based data on demographics, comorbidities and co-
medications. Additional studies were designed to capture drug utilization, safety 
and effectiveness data in primary and secondary care via physician questionnaire 
completed based on medical chart review. With an emphasis on the consistent 
definition of endpoints, protocols were developed and tailored for each study for 
submission to regulatory authorities and relevant ethics committees. Results: 
A PASS programme of 7 studies was designed. Rivaroxaban drug utilization, and 
safety and effectiveness, in comparison with standard of care, are being assessed 
using The Health Improvement Network (UK), the PHARMO Database Network (The 
Netherlands), the German Pharmacoepidemiological Research Database and the 
National Swedish Registries. The programme also includes 2 Specialist Cohort Event 
Monitoring studies to collect data on the initial treatment period in secondary care 
settings, and a complementary Modified Prescription-Event Monitoring study that 
evaluates long-term use in primary care. cOnclusiOns: This pharmacoepidemio-
logic PASS programme, with its unique and complementary approach, will monitor 
and characterize the real-life benefit–risk profile of rivaroxaban. A flexible design 
allows the accommodation of any new indications for rivaroxaban approved dur-
ing the study.
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Objectives: (1) To assess the prevalence of migraine using the National Health 
and Nutrition Examination Survey (NHANES) conducted in the general United 
States population; (2) To calculate the 10-year Framingham cardiovascular dis-
ease (CVD) and coronary heart disease (CHD) risks and compare the risks between 
migraine patients (MP) and non-migraineurs (NM). MethOds: MP were identi-
fied using the survey question: “During the past 3 months, did you have severe 
headaches or migraines?” from the 1999-2000, 2001-2002, and 2003-2004 NHANES. 
Independent chi-square tests and t-tests were used to compare differences in 
CVD or CHD risk factors between MP and NM. Multivariant ordinal logistic regres-
sions were used to examine the odds ratios of low, moderate, and high CHD and 
CVD risks between MP and NM accounting for the complex sampling design 
used by NHANES. Significance was defined as p≤ 0.05. Results: Amongst the 
total of 14,204 study subjects (6,731 men and 7,473 women), 2,895 (20.38%) sub-
jects reported having migraines or severe headaches in the past three months. 
The average age of MP was 41.8 (±16.8) years, compared to 47.4 (±19.8) years in 
the NM group. MP had a significantly higher percentage of females, with 1,962 
(67.77%) females. Subjects in the migraine group were found to have an odds 
ratio of 1.208 (95% CI, 1.033-1.412, p-value< 0.001) for moderate CHD risk, and 
an odds ratio of 0.975 (95% CI, 0.732 – 1.412, p-value< 0.001) for high CHD risk. 
Regarding CVD risk, migraine patients were found to have an odds ratio of 1.173 (95% 
CI, 0.818 – 1.683, p-value< 0.001) for moderate risk, and an odds ratio of 1.112 (95% CI, 
0.909 – 1.582, p-value< 0.001) for high risk. cOnclusiOns: Migraine appears to be 
more prevalent among younger subjects with an overall mean age of 42 years old. 
These findings also suggest a positive association between migraine and CHD risks.
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Objectives: The analysis of different non-invasive imaging strategies in a 
European population of patients with stable angina could help the identification 
of the best approach for the diagnosis of significant CAD. MethOds: In 475 pts 
(291 males, 60±9 yrs) with stable angina enrolled in the EVINCI multicenter study, 
CT coronary angiography (CTCA) and stress imaging were performed before inva-
sive coronary angiography (ICA). Significant CAD was defined as > 50% stenosis 
in the left main or > 70% stenosis in a major coronary vessel or 30-70% stenosis 
with fractional flow reserve ≤ 0.8. Nine non-invasive imaging strategies including 
CTCA or stress imaging (ECHO, CMR, SPECT or PET) alone or in combination with 
CTCA performed as first line examinations were evaluated. Combinations were 
positive if both CTCA and the stress test were positive and their performance 
was evaluated in terms of accuracy (AUC). Centres specific reimbursements were 
collected for invasive and non-invasive examination and the costs associated 
with different strategies were obtained at individual patient level by summing 
up reimbursement of the examinations involved. Results: Significant CAD was 
diagnosed at ICA in 140 patients (29%). CTCA had the highest diagnostic perfor-
mance among strategies involving single imaging modalities [0.91 (0.88-0.94)] and 
CTCA-PET among combinations [0.84 (0.74-0.93)]. Costs vary significantly among 
the strategies involving single non invasive modalities with value ranging from 
425 Euro for ECHO to 1245 Euro for PET as well as for those involving combina-
tions of imaging modalities ranging from 508 Euro for CTCA-ECHO to 870 Euro for 
CTCA-SPECT. cOnclusiOns: The diagnostic workflow for CAD detection shows 
variable effectiveness and costs according to the use of different single or com-
bined non invasive imaging modalities. Data collected in the EVINCI study offer 
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compare the effectiveness with CAS and CEA in 677 patients with symptomatic 
carotid artery stenosis in korean clinical practice. MethOds: From January 1 2008 
to December 31 2011, retrospective cohort study was conducted in 677 symptomatic 
carotid stenosis patients with more than 50% stenosis) (CAS= 346, CEA= 331) in the 
Korean hospitals (Asan medical center, Samsung medical center, Severance hospital, 
Inha university hospital, Chonnam university hospital). The primary outcome was 
stroke, myocardial infarction, or death during periprocedural (30-day) and postproce-
dural period. Results: For 677 patients over 2-year follow-up period, All death, major 
stroke, minor stroke were higher in CAS group than CEA (1.45% vs. 0.30%, 4.05% vs. 
1.81%, 3.47% vs. 3.02%, 0.58% vs. 0%). All outcomes were higher in CAS than in CEA 
within 30-day after treatment and in subsequent years, except the incidence of 30 
days-minor stroke. cOnclusiOns: CEA was superior to CAS in symptomatic patients 
with carotid stenosis. This study suggests that CEA can be considered the first-line 
therapy for symptomatic carotid artery stenosis in South Korea.
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LiVing in PAtients with unCOntrOLLed hyPertensiOn
DiCarlo L., Kim Y.A., Young J, Bezhadi Y.
Proteus Digital Health, Redwood City, CA, USA
Objectives: For patients with uncontrolled hypertension, differentiation of phar-
macological resistance from inadequate or improper medication use is key to clini-
cal management. Proteus Digital Health has developed a unique digital feedback 
system, which utilizes an Ingestible Sensor (IS) to determine medication-taking 
patterns. A wearable sensor in the form of an adhesive patch collects timing and 
taking of IS ingestions, and physiological and behavioral metrics such as heart 
rate, and patterns of activity and rest, providing insights into the patient’s day-
to-day lifestyle. This study evaluates the utility of the Proteus system in patients 
with uncontrolled hypertension. MethOds: Patients with a history of uncontrolled 
hypertension (BP> 140/90) at 5 primary care centers in the United Kingdom were 
prescribed the Proteus system for 14 days. Patients co-ingested the IS along with 
their prescribed BP medications while simultaneously wearing the patch. BP was 
measured on days 1 and 14 by a clinician, and all other parameters, such as adher-
ence, activity and rest patterns, were collected via the Proteus system. Results: 
Of the 190 patients, 21 patients had incomplete data. In the remaining 169 patients 
(89%), mean medication adherence was 88%, and mean BP decrease was -7.6 mm 
Hg systolic and -3.8 mm Hg diastolic. The system data provided diagnostic insight 
differentiating non-response vs. non-adherence. One hundred forty-eight (78%) 
patients had ≥ 70% adherence; 100 (53%) achieved blood pressure control on their 
prescribed therapy, and 48 (25%) remained uncontrolled and required modifica-
tion of their therapeutic regimen. The remaining 21 patients (11%) were identi-
fied as needing intervention to support medication adherence. cOnclusiOns: In 
patients with a history of uncontrolled hypertension, 53% achieved BP control within 
2 weeks, and 25% received an informed therapeutic intervention using the Proteus 
system. Thus, Proteus can identify specific individual needs for progressing through 
the recommended treatment pathway and for advancing toward treatment goals.
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Objectives: Randomized controlled trials (RCTs) provide the most robust evi-
dence source for making patient health care decisions. When RCT data are lacking, 
however, complementary evidence sources may also be needed. As an example of 
this, three clinical trials comparing rosuvastatin with atorvastatin were simulated 
using the Archimedes model, a validated, individual-based simulation of human 
pathophysiology and behaviours, treatment interventions and health care sys-
tems. MethOds: Comparison A assessed clinical outcomes in patients receiving 
available doses of the two drugs. Comparison B assessed the impact of initial treat-
ment decisions, with individuals randomized to receive various doses of either 
rosuvastatin or atorvastatin and eligible for treatment intensification for up to 5 
years if target lipid levels were not met. Comparison C assessed the effect of switch-
ing patients’ treatment from rosuvastatin to atorvastatin. Results: In comparison 
A, rosuvastatin was estimated to result in greater reductions than atorvastatin 
in major adverse cardiac events (MACEs) at 5 and 20 years at all doses examined 
(relative risk [RR]: 0.907,0. 892 and 0.931 at 20 years for rosuvastatin 20 mg versus 
atorvastatin 40 mg, rosuvastatin 40 mg versus atorvastatin 80 mg, and rosuvastatin 
20 mg versus atorvastatin 80 mg, respectively; P< 0.05 in all cases). In comparison 
B, outcomes were significantly better in patients initially prescribed rosuvastatin 
relative to atorvastatin (RR of MACE at 10 years: 0.919; P< 0.001). In comparison C, 
risk of MACE was significantly greater in patients who switched from rosuvastatin to 
atorvastatin, relative to those who remained on rosuvastatin (RR at 10 years: 1.115; 
P< 0.001). cOnclusiOns: In this example using the well-validated Archimedes 
model, better outcomes were predicted in patients receiving rosuvastatin than 
in those receiving atorvastatin in a variety of different settings. This provides an 
example of the utility of robust modelling approaches to generating evidence that 
is not available from clinical trials.
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CritiCAL APPrAisAL Of netwOrk metA-AnALyses eVALuAting the 
effiCACy And sAfety Of new OrAL AntiCOAguLAnts in AtriAL 
fiBriLLAtiOn strOke PreVentiOn triALs
Cope S.1, Clemens A.2, Hammès F.3, Noack H.4, Jansen J.5
1Mapi, Inc., Toronto, ON, Canada, 2Boehringer Ingelheim Pharma GmbH & Co KG, Corporate 
Devision Medicine, Ingelheim, Germany, 3Boehringer Ingelheim, Paris, France, 4Boehringer 
Ingelheim Pharma GmbH & Co KG, Medical Data Services, Ingelheim, Germany, 5Tufts University 
School of Medicine, Boston, MA, USA
stances. All 3 economic studies found MIS in the treatment of ICH was associated 
with lower costs compared to MM or CR. In one study MIS resulted in a $USD44,329 
saving in acute care costs compared to MM, primarily driven by lower hospital bed 
days (70 vs. 98.9 days). cOnclusiOns And iMPlicAtiOns OF KeY FindinGs: MIS 
in the treatment of ICH presents convincing evidence for improved efficacy over MM 
and CR. The latest clinical practice guidelines for the treatment of ICH do not yet accu-
rately reflect these latest findings and as such, current treatment practices may be 
lagging behind what the highest level of evidence suggests should be standard of care.
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Objectives: One reason of the low efficiency of cardiovascular diseases (CVD) 
treatment in Ukraine is the low adherence of patients. Modern trends improving 
the quality of treatment and increase patients compliance is use of polypills (PP). 
The aim: pharmacoeconomic assesment the feasibility of PP amlodipine and ator-
vastatin versus monodrugs in patients with hypertension and dyslipidemia (DYS) 
from the Ukrainian perspectives point of view. MethOds: The results of clinical 
studies AVALON (Granger C. B., McMurray J. J., Yusuf S. et al., 2003) were used. Cost 
minimization analysis of three regimens of patients treatment with hypertension 
and DYS during 8 weeks: PP amlodipine 5 mg + atorvastatin 10 mg; amlodipine 5 mg; 
atorvastatin 10 mg. Results: The results of the clinical research AVALON found, 
that the use of PP amlodipine+atorvastatin provides significant clinical benefit: 
the largest number of patients reached target levels of blood pressure (BP) and 
low-density lipoprotein cholesterol (LDL-C) (45.5%), versus amlodipine (8.3%), ator-
vastatin (28.6%), placebo (3.5%). The scheme using amlodipine is the most expensive 
(cost for course of treatment (CCT) € 20.28), the regimen of atorvastatin 10 mg (CCT 
€ 10.46) and the PP amlodipine+atorvastatin (CCT € 17.72) are less costly. This PP is 
more cost effective versus amlodipine monotherapy (CER = € 38.95 versus € 244.34 
per patient with target levels of BP and LDL-C) and less cost effective compared 
atorvastatin monotherapy (CER = € 36.57 per patient with target levels of BP and 
LDL-C). The cost of an additional unit of effectiveness (ICER) showed that the use of 
PP amlodipine+atorvastatin instead amlodipine provides for the treatment of each 
100 patients additional 37.2 patients achieved target levels of BP and LDL-C and 
saving € 6.88 per patient. cOnclusiOns: Pharmacotherapy of patients with hyper-
tension and DYS based on PP amlodipine+atorvastatin provides significant clinical 
benefit versus monodrugs and pharmacoeconomic advantages versus amlodipine.
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Objectives: The AMPLIFY trial compared apixaban to low-molecular-weight 
heparin (LMWH) followed by a vitamin K antagonist (VKA) for treatment and 
prevention of recurrent venous thromboembolism (VTE). The AMPLIFY-EXT trial 
compared extended treatment with apixaban to placebo in previously treated 
patients. This analysis evaluated the potential lifetime implications of apixaban 
treatment versus LMWH/VKA. MethOds: A Markov model was developed to eval-
uate the lifetime impact of treatment and prevention of VTE with apixaban (5 mg 
BID for 6 months, then 2.5 mg BID) versus LMWH/VKA. Clinical event rates were 
taken from AMPLIFY, AMPLIFY-EXT, and indirect treatment comparison. Length 
of stay for hospitalizations was taken from AMPLIFY for recurrent VTE (median 
5 days for apixaban, 6 days for LMWH/VKA) and major bleeds (median 5 days for 
apixaban, 7 days for LMWH/VKA). Sixty percent of patients with recurrent VTE 
and all patients with major bleeding were assumed to be hospitalized. Outcomes 
evaluated were events and hospital bed days avoided, number needed to treat to 
avoid a recurrent VTE, number needed to treat to harm with an additional bleed, 
and life years gained. Results: In a cohort of 1,000 patients, lifetime treatment 
with apixaban versus LMWH/VKA resulted in 6 fewer recurrent VTE events, 191 
fewer major bleeds, 707 fewer clinically relevant non-major bleeds, and 1,730 hos-
pital bed days avoided. On average, a patient treated with apixaban gained about 3 
months of life expectancy due to avoidance of VTE events and major bleeds. These 
results translated to one recurrent VTE event avoided for each 157 patients treated 
and one major bleed avoided for each 5 patients treated with apixaban versus 
warfarin. cOnclusiOns: Apixaban for treatment and prevention of VTE appears 
to be a superior alternative to LMWH/VKA, leading to fewer recurrent VTEs, bleed-
ing events, and hospital bed days resulting in a projected increase in life-expec-
tancy.
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Objectives: Carotid endarterectomy (CEA) has been recommended as the gold 
standard for the management of carotid disease in many clinical guidelines. But, 
in Korean clinical practice, carotid artery stening (CAS) was conducted more than 
CEA (21.6%) based on the national claims-data. The purpose of this study was to 
